{"id":"https://openalex.org/W2134306287","doi":"https://doi.org/10.1517/13543784.15.2.117","title":"Targeting the proteasome as a therapeutic strategy against haematological malignancies","display_name":"Targeting the proteasome as a therapeutic strategy against haematological malignancies","publication_year":2006,"publication_date":"2006-01-24","ids":{"openalex":"https://openalex.org/W2134306287","doi":"https://doi.org/10.1517/13543784.15.2.117","mag":"2134306287","pmid":"https://pubmed.ncbi.nlm.nih.gov/16433592"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.15.2.117","doi":"https://doi.org/10.1517/13543784.15.2.117","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.15.2.117","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038235561","display_name":"Robert Zygmunt Orlowski","orcid":"https://orcid.org/0000-0002-5723-4129","observed_orcids":["https://orcid.org/0000-0002-5723-4129"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Z Orlowski","raw_affiliation_strings":["Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. R_Orlowski@med.unc.edu","Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. R_Orlowski@med.unc.edu","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057867933","display_name":"Erik L. Zeger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik L Zeger","raw_affiliation_strings":["Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. R_Orlowski@med.unc.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. R_Orlowski@med.unc.edu","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I114027177"],"apc_list":null,"apc_paid":null,"fwci":0.2908,"has_fulltext":false,"cited_by_count":22,"citation_normalized_percentile":{"value":0.24582126,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"15","issue":"2","first_page":"117","last_page":"130"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9667999744415283,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9667999744415283,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.021700000390410423,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/ubiquitin-proteasome-system","display_name":"ubiquitin-proteasome system","score":0.9279999732971191},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.9670000076293945},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9890000224113464},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.6890000104904175},{"id":"https://openalex.org/keywords/chemosensitization","display_name":"chemosensitization","score":0.9710000157356262},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7990000247955322},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8519999980926514},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.6970000267028809},{"id":"https://openalex.org/keywords/myeloid-neoplasms","display_name":"myeloid neoplasms","score":0.8410000205039978}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9332777261734009},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.8009945154190063},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7153356671333313},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.6333260536193848},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5619016289710999},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5035197138786316},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.5033292174339294},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.5020897388458252},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48161834478378296},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3250582218170166},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3216029405593872},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.08332088589668274}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":true},{"descriptor_ui":"D046988","descriptor_name":"Proteasome Endopeptidase Complex","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.15.2.117","doi":"https://doi.org/10.1517/13543784.15.2.117","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.15.2.117","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:16433592","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16433592","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8100000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2108575099","display_name":"Dual Proteasome and MAPK Inhibition in Cancer Therapy","funder_award_id":"R01CA102278","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000881002","display_name":"Research Training in Hematology at UNC Chapel Hill","funder_award_id":"T32HL007149","funder_id":"https://openalex.org/F4320337338","funder_display_name":"National Heart, Lung, and Blood Institute"}],"funders":[{"id":"https://openalex.org/F4320337338","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":70,"referenced_works":["https://openalex.org/W1590553747","https://openalex.org/W1772903887","https://openalex.org/W1916870638","https://openalex.org/W1935443268","https://openalex.org/W1938721925","https://openalex.org/W1975118270","https://openalex.org/W1978377409","https://openalex.org/W1980471295","https://openalex.org/W1987583882","https://openalex.org/W1988265934","https://openalex.org/W1992978957","https://openalex.org/W2016742872","https://openalex.org/W2025253157","https://openalex.org/W2055340704","https://openalex.org/W2055744416","https://openalex.org/W2058468326","https://openalex.org/W2061632343","https://openalex.org/W2075768627","https://openalex.org/W2082230294","https://openalex.org/W2083107653","https://openalex.org/W2085806665","https://openalex.org/W2093330684","https://openalex.org/W2100608938","https://openalex.org/W2105395943","https://openalex.org/W2107154392","https://openalex.org/W2108235071","https://openalex.org/W2115219209","https://openalex.org/W2119680582","https://openalex.org/W2120590293","https://openalex.org/W2122684890","https://openalex.org/W2124560610","https://openalex.org/W2136221829","https://openalex.org/W2136735139","https://openalex.org/W2138077682","https://openalex.org/W2138102966","https://openalex.org/W2142149038","https://openalex.org/W2148216137","https://openalex.org/W2148820011","https://openalex.org/W2151968496","https://openalex.org/W2152065071","https://openalex.org/W2166043738","https://openalex.org/W2166526813","https://openalex.org/W2170220752","https://openalex.org/W2247829215","https://openalex.org/W2248466287","https://openalex.org/W2258467532","https://openalex.org/W2283588224","https://openalex.org/W2551250358","https://openalex.org/W2553186958","https://openalex.org/W2556663328","https://openalex.org/W2556667640","https://openalex.org/W2558188986","https://openalex.org/W2558538114","https://openalex.org/W2567376997","https://openalex.org/W2567614364","https://openalex.org/W2576646064","https://openalex.org/W2582367289","https://openalex.org/W2583215460","https://openalex.org/W2583529846","https://openalex.org/W2587075560","https://openalex.org/W2587772896","https://openalex.org/W2588341794","https://openalex.org/W2588611030","https://openalex.org/W2589777434","https://openalex.org/W2590580802","https://openalex.org/W2593658983","https://openalex.org/W2596102704","https://openalex.org/W2980167576","https://openalex.org/W2991927207","https://openalex.org/W4244900710"],"related_works":["https://openalex.org/W2105329712","https://openalex.org/W2126947411","https://openalex.org/W1964175291","https://openalex.org/W1964956799","https://openalex.org/W2005975820","https://openalex.org/W2001742494","https://openalex.org/W2038142912","https://openalex.org/W2408884886","https://openalex.org/W2068100481","https://openalex.org/W4234188779"],"abstract_inverted_index":{"The":[0,121],"ubiquitin-proteasome":[1],"pathway":[2],"is":[3,32,56,86,148],"responsible":[4],"for":[5],"the":[6,16,33,39,111,127,142],"vast":[7],"majority":[8],"of":[9,15,65,98,113,124,129,141],"regulated":[10],"eukaryotic":[11],"intracellular":[12],"proteolysis.":[13],"Inhibition":[14],"proteasome":[17,35],"induces":[18],"beneficial":[19],"antitumour":[20],"effects":[21],"by":[22],"blocking":[23],"cell-cycle":[24],"progression,":[25],"inducing":[26],"apoptosis":[27],"and":[28,94,100,106,118,133],"suppressing":[29],"angiogenesis.":[30],"Bortezomib":[31],"first":[34],"inhibitor":[36],"to":[37,58,91],"reach":[38],"clinical":[40],"arena,":[41],"where":[42],"Phase":[43],"I":[44],"-":[45],"III":[46],"trials":[47],"verified":[48],"its":[49],"activity":[50,80,112,128],"against":[51,145],"relapsed/refractory":[52],"multiple":[53],"myeloma.":[54],"Testing":[55],"ongoing":[57],"determine":[59],"bortezomib's":[60],"role":[61],"in":[62,73,76,116,134],"front-line":[63],"therapy":[64],"this":[66],"plasma":[67],"cell":[68],"dyscrasia,":[69],"as":[70,72,139],"well":[71],"non-Hodgkin's":[74],"lymphoma,":[75],"which":[77],"encouraging":[78],"single-agent":[79],"has":[81],"been":[82],"seen.":[83],"Proteasome":[84],"inhibition":[85],"also":[87],"a":[88],"rational":[89],"strategy":[90],"overcome":[92],"chemoresistance":[93],"induce":[95],"chemosensitisation.":[96],"Combinations":[97],"bortezomib":[99],"other":[101],"agents":[102],"have":[103],"enhanced":[104],"efficacy,":[105],"additional":[107],"studies":[108],"are":[109],"probing":[110],"several":[114],"regimens":[115],"lymphoid":[117],"myeloid":[119],"malignancies.":[120],"current":[122],"state":[123],"knowledge":[125],"about":[126],"bortezomib,":[130],"both":[131],"alone":[132],"combination":[135],"with":[136],"standard":[137],"chemotherapeutics,":[138],"part":[140],"emerging":[143],"armamentarium":[144],"haematological":[146],"malignancies":[147],"reviewed.":[149]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}